PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Open accessAbstract
PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-degradation strategy that has emerged in recent years. It uses bifunctional small molecules to induce the ubiquitination and degradation of target proteins through the ubiquitin–proteasome system. PROTACs can not only be used as potential clinical treatments for diseases such as cancer, immune disorders, viral infections, and neurodegenerative diseases, but also provide unique chemical knockdown tools for biological research in a catalytic, reversible, and rapid manner. In 2019, our group published a review article “PROTACs: great opportunities for academia and industry” in the journal, summarizing the representative compounds of PROTACs reported before the end of 2019. In the past 2 years, the entire field of protein degradation has experienced rapid development, including not only a large increase in the number of research papers on protein-degradation technology but also a rapid increase in the number of small-molecule degraders that have entered the clinical and will enter the clinical stage. In addition to PROTAC and molecular glue technology, other new degradation technologies are also developing rapidly. In this article, we mainly summarize and review the representative PROTACs of related targets published in 2020–2021 to present to researchers the exciting developments in the field of protein degradation. The problems that need to be solved in this field will also be briefly introduced.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Protein regulation can be categorized into two primary classes based on the disease mechanism: protein degradation and protein stabilization.
“Protein regulation can be categorized into two primary classes based on the disease mechanism: protein degradation and protein stabilization.476”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [476]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145 · see citing works
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · see citing works
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554 · see citing works
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · see citing works
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931 · see citing works
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846 · see citing works
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · see citing works
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · see citing works
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · see citing works
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489 · see citing works
The Human Transcription Factors
Lambert, S. A., Jolma, A., Campitelli, L. F., Das, P. K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T. R., & Weirauch, M. T. (2018) · Cell · doi:10.1016/j.cell.2018.01.029 · Cited by 3,399 · see citing works
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276 · see citing works
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · see citing works
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110 · see citing works
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works
Transcriptional Regulation in Mammalian Cells by Sequence-Specific DNA Binding Proteins
Mitchell, P. J., & Tjian, R. (1989) · Science · doi:10.1126/science.2667136 · Cited by 3,046 · see citing works
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · see citing works
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · see citing works
An updated evolutionary classification of CRISPR–Cas systems
Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., Saunders, S. J., Barrangou, R., Brouns, S. J. J., Charpentier, E., Haft, D. H., et al. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3569 · Cited by 2,504 · see citing works
Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection
Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigne-Roussel, A., Thomas, G. D., Philpott, D. J., & Sansonetti, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200651200 · Cited by 2,397 · see citing works
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,244 · see citing works
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works
Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132 · see citing works
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,007 · see citing works
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945 · see citing works
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · see citing works
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,875 · see citing works
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,837 · see citing works
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Bockstaele, D. R. V., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,766 · see citing works
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · see citing works
Structure and ligand of a histone acetyltransferase bromodomain
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732 · see citing works
Sirtuins in mammals: insights into their biological function
Michán, S., & Sinclair, D. A. (2007) · Biochemical Journal · doi:10.1042/bj20070140 · Cited by 1,719 · see citing works
Mechanisms and functions of p38 MAPK signalling
Cuadrado, A., & Nebreda, Á. R. (2010) · Biochemical Journal · doi:10.1042/bj20100323 · Cited by 1,679 · see citing works
G‐Quartets 40 Years Later: From 5′‐GMP to Molecular Biology and Supramolecular Chemistry
Davis, J. T. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200300589 · Cited by 1,629 · see citing works
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · see citing works
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536 · see citing works
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,519 · see citing works
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,480 · see citing works
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · see citing works
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J., Schwartz, D., Villarino, A. V., Gadina, M., Mcinnes, I., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,472 · see citing works
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471 · see citing works
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407 · see citing works
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · see citing works
FAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381 · see citing works
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,380 · see citing works
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,376 · see citing works
An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control
Clevers, H. C., Loh, K. M., & Nusse, R. (2014) · Science · doi:10.1126/science.1248012 · Cited by 1,351 · see citing works
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · see citing works
IRAK-M Is a Negative Regulator of Toll-like Receptor Signaling
Kobayashi, K. S., Hernandez, L. D., Galán, J. E., Janeway, C. A., Medzhitov, R. M., & Flavell, R. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00827-9 · Cited by 1,289 · see citing works
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · see citing works
Toll-Like Receptor Signaling Pathways
Barton, G. M., & Medzhitov, R. M. (2003) · Science · doi:10.1126/science.1085536 · Cited by 1,270 · see citing works
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226 · see citing works
Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems
Shmakov, S., Abudayyeh, O. O., Makarova, K. S., Wolf, Y. I., Gootenberg, J. S., Semenova, E., Станиславович, М. Л., Joung, J., Konermann, S., Severinov, K., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.008 · Cited by 1,221 · see citing works
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,186 · see citing works
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,173 · see citing works
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131 · see citing works
(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,123 · see citing works
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · see citing works
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works
Helical Assembly in the MyD88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling
Lin, S.-C., Lo, Y.-C., & Wu, H. (2010) · Nature · doi:10.1038/nature09121 · Cited by 1,111 · see citing works
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N. G., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,106 · see citing works
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105 · see citing works
Protein arginine methyltransferases and cancer
Yang, Y., & Bedford, M. T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3409 · Cited by 1,104 · see citing works
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062 · see citing works
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · see citing works
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 1,010 · see citing works
Haft, D. H., Selengut, J., Mongodin, E. F., & Nelson, K. E. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0010060 · Cited by 981 · see citing works
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 980 · see citing works
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 972 · see citing works
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 965 · see citing works
Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors
Pillaiyar, T., Manickam, M., & Namasivayam, V. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1256882 · Cited by 932 · see citing works
CRISPR/Cas Systems towards Next-Generation Biosensing
Li, Y., Li, S., Wang, J., & Liu, G. (2019) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.12.005 · Cited by 915 · see citing works
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904 · see citing works
Self-citationFrom basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903 · see citing works
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature · doi:10.1038/nature24028 · Cited by 858 · see citing works
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852 · see citing works
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835 · see citing works
CRISPR-Cas immunity in prokaryotes
Marraffini, L. A. (2015) · Nature · doi:10.1038/nature15386 · Cited by 830 · see citing works
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.8 · Cited by 815 · see citing works
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martı́n-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 812 · see citing works
Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
Esvelt, K. M., Mali, P., Braff, J. L., Moosburner, M., Yaung, S. J., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2681 · Cited by 786 · see citing works
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776 · see citing works
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770 · see citing works
Regulation of MLL1 H3K4 methyltransferase activity by its core components
Dou, Y., Milne, T. A., Ruthenburg, A. J., Lee, S., Lee, J. W., Verdine, G. L., Allis, C. D., & Roeder, R. G. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1128 · Cited by 764 · see citing works
Inhibiting NF-κB activation by small molecules as a therapeutic strategy
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762 · see citing works
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
Zhang, X. M., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J. M., Olashaw, N., Parsons, J. T., Yang, X., Dent, S., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.033 · Cited by 731 · see citing works
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & den Eynde, B. J. V. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 708 · see citing works
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 705 · see citing works
Aurora-A — A guardian of poles
Marumoto, T., Zhang, D., & Saya, H. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1526 · Cited by 698 · see citing works
Aptamers come of age – at last
Bunka, D. H. J., & Stockley, P. G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1458 · Cited by 695 · see citing works
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688 · see citing works
Self-citationForkhead box proteins: tuning forks for transcriptional harmony.
Lam, E. W.-F., Brosens, J. J., Gomes, A. R., & Koo, C.-Y. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3539 · Cited by 684 · see citing works
Regulation of RAF protein kinases in ERK signalling
Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 683 · see citing works
Guo, Z., Li, C., Gao, M., Han, X., Zhang, Y., Zhang, W., & Li, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202014556 · Cited by 680 · see citing works
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 671 · see citing works
Berthet, C., Aleem, E. A., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 665 · see citing works
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 651 · see citing works
Self-citationDirect small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · see citing works
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works
Histone lysine demethylases: emerging roles in development, physiology and disease
Shi, Y. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2218 · Cited by 603 · see citing works
Exploiting the folate receptor α in oncology
Scaranti, M., Cojocaru, E., Banerjee, S. N., & Banerji, U. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0339-5 · Cited by 601 · see citing works
Targeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599 · see citing works
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596 · see citing works
Folate-targeted therapeutic and imaging agents for cancer
Low, P. S., & Kularatne, S. A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.022 · Cited by 586 · see citing works
A Call for Systematic Research on Solute Carriers
César‐Razquin, A., Snijder, B., Frappier‐Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R. A., Hepworth, D., Hediger, M. A., Edwards, A. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.022 · Cited by 578 · see citing works
Inhibitors of NF-κB signaling: 785 and counting
Gilmore, T. D., & Herscovitch, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209982 · Cited by 571 · see citing works
Moerke, N., Aktas, H., Chen, H., Cantel, S., Reibarkh, M., Fahmy, A., Gross, J., Degterev, A., Yuan, J., Chorev, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.046 · Cited by 568 · see citing works
Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002) · Nature Cell Biology · doi:10.1038/ncb867 · Cited by 566 · see citing works
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3702 · Cited by 564 · see citing works
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562 · see citing works
Leamon, C. P. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.008 · Cited by 559 · see citing works
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Stopa, N., Krebs, J. E., & Shechter, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1847-9 · Cited by 529 · see citing works
Targeting ALK: Precision Medicine Takes on Drug Resistance
Lin, J. J., Riely, G. J., & Shaw, A. T. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1123 · Cited by 528 · see citing works
MYC as a target for cancer treatment
Duffy, M. J., O’Grady, S., Tang, M., & Crown, J. P. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102154 · Cited by 524 · see citing works
Lorenzo, A. D., & Bedford, M. T. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.11.010 · Cited by 511 · see citing works
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504 · see citing works
A dimerization-dependent mechanism drives RAF catalytic activation
Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., & Therrien, M. (2009) · Nature · doi:10.1038/nature08314 · Cited by 490 · see citing works
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Xu, J., Wu, R., & O’Malley, B. W. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2695 · Cited by 487 · see citing works
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487 · see citing works
Morishita, R., Gibbons, G. H., Horiuchi, M., Ellison, K., Nakama, M., Zhang, L., Kaneda, Y., Ogihara, T., & Dzau, V. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5855 · Cited by 479 · see citing works
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated <i>Myc</i> regulation
Shi, J., Whyte, W. A., Zepeda-Mendoza, C. J., Milazzo, J. P., Shen, C., Roe, J.-S., Minder, J. L., Mercan, F., Wang, E., Eckersley-Maslin, M. A., et al. (2013) · Genes & Development · doi:10.1101/gad.232710.113 · Cited by 463 · see citing works
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 461 · see citing works
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457 · see citing works
Targeted Degradation of Oncogenic KRAS <sup>G12C</sup> by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450 · see citing works
L‐tyrosine and L‐dihydroxyphenylalanine as hormone‐like regulators of melanocyte functions
Slominski, A. T., Zmijewski, M. A., & Pawelek, J. M. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00898.x · Cited by 449 · see citing works
S ELECTIVITY IN N EUROTROPHIN S IGNALING : Theme and Variations
Segal, R. A. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131421 · Cited by 447 · see citing works
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437 · see citing works
Low molecular weight inhibitors of Myc–Max interaction and function
Yin, X., Giap, C., Lazo, J. S., & Prochownik, E. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206641 · Cited by 426 · see citing works
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419 · see citing works
Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy
Zhang, C., Zeng, Z., Cui, D. M., He, S., Jiang, Y., Li, J., Huang, J., & Pu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23194-w · Cited by 417 · see citing works
Yang, C., Li, Z., Bhatt, T., Dickler, M. N., Giri, D. D., Scaltriti, M., Baselga, J. M., Rosen, N. X., & Chandarlapaty, S. (2016) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 413 · see citing works
The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation
Leprivier, G., Remke, M., Rotblat, B., Dubuc, A. M., Mateo, A.-R. F., Kool, M., Agnihotri, S., El-Naggar, A. M., Yu, B., Somasekharan, S. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.055 · Cited by 412 · see citing works
Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404 · see citing works
Han, X., Wang, C., Qin, C., Xiang, W., Fernández‐Salas, E., Yang, C., Wang, M., Zhao, L., Xu, T., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01631 · Cited by 404 · see citing works
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination
Boyault, C., Sadoul, K., Pabion, M., & Khochbin, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210614 · Cited by 397 · see citing works
Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394 · see citing works
BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis
Edwards, P. A., Kast-Woelbern, H. R., & Anisfeld, A. M. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30180-2 · Cited by 387 · see citing works
Light-Induced Protein Degradation with Photocaged PROTACs
Xue, G., Wang, K., Zhou, D., Zhong, H., & Pan, Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06422 · Cited by 377 · see citing works
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374 · see citing works
The FERM domain: organizing the structure and function of FAK
Frame, M. C., Patel, H., Serrels, B., Lietha, D., & Eck, M. J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2996 · Cited by 372 · see citing works
Zhou, B. N., Hu, J., Xu, F., Chen, Z., Bai, L., Fernández‐Salas, E., Lin, M., Liu, L., Yang, C., Zhao, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01816 · Cited by 372 · see citing works
Krook, M. A., Reeser, J. W., Ernst, G., Barker, H. D., Wilberding, M., Li, G., Chen, H., & Roychowdhury, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01157-0 · Cited by 369 · see citing works
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 362 · see citing works
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Donovan, K. A., Ferguson, F. M., Bushman, J. W., Eleuteri, N. A., Bhunia, D., Ryu, S., Tan, L., Shi, K., Yue, H., Liu, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.038 · Cited by 359 · see citing works
Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00285 · Cited by 350 · see citing works
Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction
Schreiner, P., Chen, X., Husnjak, K., Randles, L., Zhang, N., Elsasser, S., Finley, D. J., Đikić, I., Walters, K. J., & Groll, M. (2008) · Nature · doi:10.1038/nature06924 · Cited by 344 · see citing works
Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation
Kleine, H., Poręba, E., Leśniewicz, K., Hassa, P. O., Hottiger, M. O., Litchfield, D. W., Shilton, B. H., & Lüscher, B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.009 · Cited by 340 · see citing works
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 340 · see citing works
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 336 · see citing works
Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336 · see citing works
Pilarsky, C. P., Wenzig, M., Specht, T., Saeger, H. D., & Grützmann, R. (2004) · Neoplasia · doi:10.1593/neo.04277 · Cited by 330 · see citing works
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325 · see citing works
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation
Dubbury, S. J., Boutz, P. L., & Sharp, P. A. (2018) · Nature · doi:10.1038/s41586-018-0758-y · Cited by 318 · see citing works
Autoregulatory Mechanisms in Protein-tyrosine Kinases
Hubbard, S. R., Mohammadi, M., & Schlessinger, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.11987 · Cited by 317 · see citing works
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Xiao, L., Parolia, A., Qiao, Y., Bawa, P., Eyunni, S., Mannan, R., Carson, S. E., Chang, Y., Wang, X., Zhang, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04246-z · Cited by 315 · see citing works
Cancer Selective Target Degradation by Folate-Caged PROTACs
Liu, J., Chen, H., Liu, Y., Shen, Y., Meng, F., Kanıskan, H. Ü., Jin, J. J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00451 · Cited by 312 · see citing works
Self-citationAptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
He, S., Gao, F., Ma, J., Ma, H., Dong, G., & Sheng, C. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202107347 · Cited by 309 · see citing works
Kita, T., Brown, M. S., & Goldstein, J. L. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109938 · Cited by 306 · see citing works
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Dai, S., Zhou, Z. M., Chen, Z., Xu, G., & Chen, Y. (2019) · Cells · doi:10.3390/cells8060614 · Cited by 297 · see citing works
Sun, Y., Zhao, X., Ding, N., Gao, H., Wu, Y., Yang, Y., Zhao, M., Hwang, J., Song, Y., Liu, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0055-1 · Cited by 295 · see citing works
Self-citationTumor detection using folate receptor-targeted imaging agents
Sega, E. I., & Low, P. S. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9155-6 · Cited by 291 · see citing works
Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners
Muramatsu, T. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv127 · Cited by 289 · see citing works
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, C. E., Tilley, W. D., & Wang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 285 · see citing works
Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281 · see citing works
He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15838-0 · Cited by 280 · see citing works
Self-citationRellos, P., Pike, A. C. W., Niesen, F. H., Salah, E., Lee, W. H., von Delft, F., & Knapp, S. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000426 · Cited by 279 · see citing works
Feeding induces cholesterol biosynthesis via the mTORC1–USP20–HMGCR axis
Lu, X.-Y., Shi, X., Hu, A., Wang, J.-Q., Ding, Y., Jiang, W., Sun, M., Zhao, X., Luo, J., Qi, W., et al. (2020) · Nature · doi:10.1038/s41586-020-2928-y · Cited by 279 · see citing works
Molecular Architecture of the Multiprotein Splicing Factor SF3b
Golas, M. M., Sander, B. O., Will, C. L., Lührmann, R., & Stark, H. (2003) · Science · doi:10.1126/science.1084155 · Cited by 277 · see citing works
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Zeng, M., Xiong, Y., Safaee, N., Nowak, R. P., Donovan, K. A., Yuan, C. J., Nabet, B., Gero, T. W., Feru, F., Li, L., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.12.006 · Cited by 275 · see citing works
Development of dual and selective degraders of cyclin-dependent kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272 · see citing works
Intracellular allosteric antagonism of the CCR9 receptor
Oswald, C., Rappas, M., Kean, J., Dore, A. S., Errey, J. C., Bennett, K. A., Deflorian, F., Christopher, J. A., Jazayeri, A., Mason, J. S., et al. (2016) · Nature · doi:10.1038/nature20606 · Cited by 263 · see citing works
Eskens, F. A. L. M., Ramos, F. J., Burger, H., O’Brien, J. P., Piera, A., de Jonge, M. J. A., Mizui, Y., Wiemer, E. A. C., Carreras, M. J., Baselga, J. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0485 · Cited by 260 · see citing works
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258 · see citing works
Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo
Ismail, S. A., Chen, Y.-X., Rusinova, A., Chandra, A., Bierbaum, M., Gremer, L., Triola, G., Waldmann, H., Bastiaens, P. I. H., & Wittinghofer, A. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.686 · Cited by 252 · see citing works
Targeting Cdc20 as a novel cancer therapeutic strategy
Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z. P., & Wei, W. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.002 · Cited by 251 · see citing works
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
Imaide, S., Riching, K. M., Makukhin, N., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N., Mahan, S. D., Murphy, N., Cowan, A. D., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00878-4 · Cited by 251 · see citing works
Structure‐Based Design of a Macrocyclic PROTAC
Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., & Ciulli, A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914396 · Cited by 251 · see citing works
A Positive Feedback Loop of lncRNA- PVT1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion
Xu, M., Wang, Y., Weng, W., Wei, P., Qi, P., Zhang, Q., Tan, C., Ni, S., Dong, L., Yang, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0742 · Cited by 249 · see citing works
TF-PROTACs Enable Targeted Degradation of Transcription Factors
Liu, J., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03852 · Cited by 247 · see citing works
Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245 · see citing works
Papillon, J. P. N., Nakajima, K., Adair, C. D., Hempel, J., Jouk, A. O., Karki, R. G., Mathieu, S., Möbitz, H., Ntaganda, R., Smith, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01318 · Cited by 244 · see citing works
DNA and RNA Quadruplex-Binding Proteins
Brázda, V., Hároníková, L., Liao, J. C. C., & Fojta, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151017493 · Cited by 243 · see citing works
Wang, W., Zhou, Q., Jiang, T., Li, S., Ye, J., Zheng, J., Wang, X., Liu, Y., Deng, M., Ke, D., et al. (2021) · Theranostics · doi:10.7150/thno.55680 · Cited by 242 · see citing works
Self-citationDiscovery of a first-in-class EZH2 selective degrader
Ma, A., Στρατικόπουλος, Η., Park, K., Wei, J., Martin, T. C., Yang, X., Schwarz, M. C., Leshchenko, V. V., Rialdi, A., Dale, B., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0421-4 · Cited by 240 · see citing works
Bulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237 · see citing works
Exploitation of EP300 and CREBBP Lysine Acetyltransferases by CancerPreprint
Attar, N., & Kurdistani, S. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026534 · Cited by 235 · see citing works
Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233 · see citing works
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
Mares, A., Miah, A. H., Smith, I. E. D., Rackham, M., Thawani, A. R., Cryan, J., Haile, P. A., Votta, B. J., Beal, A. M., Capriotti, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0868-6 · Cited by 232 · see citing works
Zur, A. A., & Brandeis, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.792 · Cited by 231 · see citing works
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., Xu, T., Wang, M., Yang, C., Chinnaswamy, K., Stuckey, J. A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01393 · Cited by 229 · see citing works
Optical Control of Small Molecule-Induced Protein Degradation
Naro, Y., Darrah, K. E., & Deiters, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12718 · Cited by 226 · see citing works
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L., & Chandarlapaty, S. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0001-z · Cited by 222 · see citing works
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Robb, C. M., Contreras, J. I., Kour, S., Taylor, M., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 221 · see citing works
Guo, W., Qi, X., Yu, X., Liu, Y., Chung, C.-I., Bai, F., Lin, X., Lu, D., Wang, L., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17997-6 · Cited by 220 · see citing works
Self-citationARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
Neklesa, T. K., Snyder, L. B., Willard, R. R., Vitale, N., Pizzano, J., Gordon, D., Bookbinder, M., Macaluso, J., Dong, H., Ferraro, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.259 · Cited by 219 · see citing works
PROTAC-DB: an online database of PROTACs
Weng, G., Shen, C., Cao, D., Gao, J., Dong, X., He, Q., Yang, B., Li, D., Wu, J., & Hou, T. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa807 · Cited by 219 · see citing works
Nairn, A. C., Bhagat, B., & Palfrey, H. C. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7939 · Cited by 218 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- [203]Georg EW Phthalimide conjugation as a strategy for in vivo target protein degradation Science 2015 348 1376 1381 10.1126/science.aab1433 25999370 PMC4937790 · DOI · Paper page
- [306]Yang C Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence Oncogene 2016 36 2255 2264 10.1038/onc.2016.379 27748766 PMC5393973 · DOI
- [502]Zhou B Discovery of a small-molecule degrader of bromodomain and extra-terminal(BET) proteins with picomolar cellular potencies and capable of achieving tumor regression J. Med. Chem. 2018 61 462 481 10.1021/acs.jmedchem.6b01816 28339196 PMC5788414 · DOI
- [505]Raina K PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer Proc. Natl Acad. Sci. USA 2016 113 7124 7129 10.1073/pnas.1521738113 27274052 PMC4932933 · DOI · Paper page
- [522]Mu XP Bai LT Xu YJ Wang JY Lu HB Protein targeting chimeric molecules specific for dual bromodomain 4(BRD4) and Polo-like kinase 1(PLK1) proteins in acute myeloidleukemia cells Biochem. Biophys. Res. Commun. 2019 521 833 839 10.1016/j.bbrc.2019.11.007 31708096 · DOI
Cited by
Sorted by citations
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works
“…such as selective inhibitors, 67 dual-target inhibitors, 68,69 allosteric modulators, 70,71 covalent inhibitors, 72 proteolysis-targeting chimeras (PROTACs) 73 and protein-protein interaction (PPI) modulators, 74,75 aiming for more effective clinical translation from outcomes of research.”
BackgroundRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313 · see citing works
Self-citationFGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Katoh, M., Loriot, Y., Brandi, G., Tavolari, S., Wainberg, Z., & Katoh, M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00869-z · Cited by 183 · see citing works
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02024-9 · Cited by 192 · see citing works
H2AX: A key player in DNA damage response and a promising target for cancer therapy
Prabhu, K. S., Kuttikrishnan, S., Ahmad, N., Habeeba, U., Mariyam, Z., Suleman, M., Bhat, A. A., & Shahab Uddin, M. S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116663 · Cited by 174 · see citing works
Kim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 159 · see citing works
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 108 · see citing works
Self-citationDNA Damage and Its Role in Cancer Therapeutics
Moon, J., Kitty, I., Renata, K., Qin, S., Zhao, F., & Kim, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054741 · Cited by 77 · see citing works
Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs
Chen, N., Zhang, Z., Liu, X., Wang, H., Guo, R.-C., Wang, H., Hu, B., Shi, Y., Zhang, P., Liu, Z., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00826 · Cited by 90 · see citing works
Current advances and development strategies of orally bioavailable PROTACs
Zeng, S., Ye, Y., Xia, H., Min, J., Xu, J., Wang, Z., Pan, Y., Zhou, X., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115793 · Cited by 89 · see citing works
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
Sun, D., Zhang, J., Dong, G., He, S., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01159 · Cited by 88 · see citing works
Ma, Z., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01818 · Cited by 80 · see citing works
Antiviral PROTACs: Opportunity borne with challenge
Liang, J., Wu, Y., Lan, K., Dong, C., Wu, S., Li, S., & Zhou, H. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100092 · Cited by 74 · see citing works
Pan, S., Ding, A., Li, Y., Sun, Y., Zhan, Y., Ye, Z., Song, N., Peng, B., Li, L., Huang, W., et al. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00056g · Cited by 71 · see citing works
Chen, S., Cui, J., Chen, H., Yu, B., & Long, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115911 · Cited by 70 · see citing works
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 67 · see citing works
Targeting androgen receptor degradation with PROTACs from bench to bedside
Jia, X., & Han, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114112 · Cited by 67 · see citing works
Bonomini, A., Mercorelli, B., & Loregian, A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05611-1 · Cited by 67 · see citing works
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022) · Molecules · doi:10.3390/molecules27248828 · Cited by 64 · see citing works
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Chen, S., Li, X., Li, Y., Xing, Y., Geng, C., Gao, S., Li, J., Ma, B., Wang, Z., Lu, W., et al. (2022) · Theranostics · doi:10.7150/thno.75444 · Cited by 64 · see citing works
Thomas, J. E., Wang, M., Jiang, W., Wang, M., Wang, L., Wen, B., Sun, D., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00492 · Cited by 61 · see citing works
Xiao, L., Liu, Y., Chen, H., & Shen, L. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2219470 · Cited by 59 · see citing works
Self-citationHarnessing the cyclization strategy for new drug discovery
Tang, K., Wang, S., Gao, W., Song, Y., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.022 · Cited by 58 · see citing works
Novel approaches to targeted protein degradation technologies in drug discovery
Xue, Y., Bolinger, A. A., & Zhou, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2187777 · Cited by 59 · see citing works
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 57 · see citing works
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL
Nayak, D., Lv, D., Yuan, Y., Zhang, P., Hu, W., Nayak, A., Ruben, E. A., Lv, Z., Sung, P., Hromas, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46922-4 · Cited by 55 · see citing works
Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
Tashima, T. (2023) · Antibodies · doi:10.3390/antib12030043 · Cited by 55 · see citing works
Drug discovery inspired by bioactive small molecules from nature
Kim, S., Lim, S.-W., & Choi, J. (2022) · Animal Cells and Systems · doi:10.1080/19768354.2022.2157480 · Cited by 54 · see citing works
Plesniak, M. P., Taylor, E. K., Eisele, F., Kourra, C. M. B. K., Michaelides, I. N., Oram, A., Wernevik, J., Valencia, Z. S., Rowbottom, H., Mann, N., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00314 · Cited by 51 · see citing works
Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery
Espinoza-Chávez, R. M., Salerno, A., Liuzzi, A., Ilari, A., Milelli, A., Uliassi, E., & Bolognesi, M. L. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00063 · Cited by 50 · see citing works
Danishuddin, M., Jamal, M. S., Song, K. S., Lee, K., Kim, J.-J., & Park, Y. (2023) · Pharmaceuticals · doi:10.3390/ph16121649 · Cited by 50 · see citing works
Zhu, H., Wang, J., Zhang, Q., Pan, X., & Zhang, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108371 · Cited by 48 · see citing works
Yu, X., Li, D., Kottur, J., Kim, H. S., Herring, L. E., Yu, Y., Xie, L., Hu, X., Chen, X., Cai, L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01521 · Cited by 43 · see citing works
Sun, N., Kabir, M., Lee, Y., Xie, L., Hu, X., Velez, J., Chen, X., Kanıskan, H. Ü., & Jin, J. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01505 · Cited by 43 · see citing works
Progress in the controllability technology of PROTAC
He, X. W., Weng, Z., & Zou, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116096 · Cited by 42 · see citing works
Degraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 44 · see citing works
Rej, R. K., Allu, S. R., Roy, J., Acharyya, R. K., Kiran, I. N. C., Addepalli, Y., & Dhamodharan, V. (2024) · Pharmaceuticals · doi:10.3390/ph17040494 · Cited by 42 · see citing works
Degradation‐Based Protein Profiling: A Case Study of Celastrol
Ni, Z., Shi, Y., Liu, Q., Wang, L., Sun, X., & Rao, Y. (2024) · Advanced Science · doi:10.1002/advs.202308186 · Cited by 42 · see citing works
Self-citationCo-delivery of PROTAC and siRNA via novel liposomes for the treatment of malignant tumors
Zhang, W., Jin, Y., Wang, J., Gu, M., Wang, Y., Zhang, X., Zhang, Y., Yu, W., Liu, Y., Yuan, W., et al. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.08.185 · Cited by 42 · see citing works
Self-citationDrug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Ma, Z., Bolinger, A. A., Chen, H., & Zhou, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00948 · Cited by 41 · see citing works
Desantis, J., Bazzacco, A., Eleuteri, M., Tuci, S., Bianconi, E., Macchiarulo, A., Mercorelli, B., Loregian, A., & Goracci, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116202 · Cited by 41 · see citing works
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Tecik, M., & Adan, A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s384293 · Cited by 42 · see citing works
Yu, X., Xu, J., Cahuzac, K. M., Xie, L., Shen, Y., Chen, X., Liu, J., Parsons, R. E., & Jin, J. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01454 · Cited by 39 · see citing works
Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39 · see citing works
Zhang, J., Ma, C., Yu, Y., Liu, C., Fang, L., & Rao, H. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104994 · Cited by 39 · see citing works
Chang, Q., Li, J., Deng, Y. W., Zhou, R., Wang, B., Wang, Y., Zhang, M., Huang, X., & Li, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01468 · Cited by 39 · see citing works
Xin, L., Wang, C., Cheng, Y., Wang, H., Guo, X., Deng, X., Deng, X., Xie, B., Hu, H., Min, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00196 · Cited by 38 · see citing works
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 44 · see citing works
Synthetic circRNA therapeutics: innovations, strategies, and future horizons
Cai, J., Qiu, Z., Cho, W. C. S., Liu, Z., Chen, S., Li, H., Chen, K., Li, Y., Zuo, C., & Qiu, M. (2024) · MedComm · doi:10.1002/mco2.720 · Cited by 38 · see citing works
Antiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 40 · see citing works
What influences the activity of Degrader−Antibody conjugates (DACs)
Guo, Y., Li, X., Xie, Y., & Wang, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116216 · Cited by 35 · see citing works
Research progress of PROTACs for neurodegenerative diseases therapy
Cai, Z., Yang, Z., Li, H., & Fang, Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107386 · Cited by 35 · see citing works
An updated patent review of BRD4 degraders
Ma, Z., Zhang, C., Bolinger, A. A., & Zhou, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2400166 · Cited by 34 · see citing works
DNA damage response in breast cancer and its significant role in guiding novel precise therapies
Li, J., Jia, Z., Dong, L., Cao, H., Huang, Y.-S., Xu, H.-Y., Xie, Z.-X., Jiang, Y.-W., Wang, X., & Liu, J.-Q. (2024) · Biomarker Research · doi:10.1186/s40364-024-00653-2 · Cited by 34 · see citing works
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
Wang, C., Zhang, Y., Chen, W., Wang, Y., & Xing, D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188927 · Cited by 33 · see citing works
Ha, S., Zhu, J., Xiang, H., & Luo, G. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109192 · Cited by 34 · see citing works
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Salama, A. K. A. A., Trkulja, M. V., Casanova, E., & Uras, I. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315440 · Cited by 35 · see citing works
Target protein degradation by protacs: A budding cancer treatment strategy
Choudhary, D., Kaur, A., Singh, P., Chaudhary, G., Kaur, R., Bayan, M. F., Chandrasekaran, B., Marji, S. M., & Ayman, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108525 · Cited by 31 · see citing works
RIPTACs: A groundbreaking approach to drug discovery
Ma, Z., Bolinger, A. A., & Zhou, J. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103774 · Cited by 32 · see citing works
Rational Prediction of PROTAC-Compatible Protein–Protein Interfaces by Molecular Docking
Pereira, G. P., Jiménez‐García, B., Pellarin, R., Launay, G., Wu, S., Martin, J., & Souza, P. C. T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01154 · Cited by 32 · see citing works
Sabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2338100 · Cited by 33 · see citing works
Versatile Split-and-Mix Liposome PROTAC Platform for Efficient Degradation of Target Protein In Vivo
Song, C., Jiao, Z., Hou, Z., Xing, Y., Sha, X., Wang, Y., Chen, J., Liu, S., Li, Z., & Yin, F. (2024) · JACS Au · doi:10.1021/jacsau.4c00278 · Cited by 31 · see citing works
Tu, Y., Dai, G., Chen, Y., Tan, L., Liu, H., & Chen, M. (2025) · Exploration · doi:10.1002/exp.20240247 · Cited by 31 · see citing works
Park, K., Qin, L., Kabir, M., Luo, K., Dale, B., Zhong, Y., Kim, A., Wang, G. G., Kanıskan, H. Ü., & Jin, J. J. (2023) · Advanced Science · doi:10.1002/advs.202205573 · Cited by 31 · see citing works
Fu, X., Huang, J., Chen, X., Xie, D., Chen, H., Liang, Z., Wang, Z., Liang, Y., Lü, A., & Liang, C. (2024) · Theranostics · doi:10.7150/thno.99588 · Cited by 30 · see citing works
Alfayomy, A. M., Ashry, R., Kansy, A. G., Sarnow, A., Erdmann, F., Schmidt, M., Krämer, O. H., & Sippl, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116167 · Cited by 29 · see citing works
Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy
Liu, L., Qiu, Y., Suo, Y., Tong, S., Wang, Y., Zhang, X., Chen, L., Huang, Y., Zhou, H., Zhou, H., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.016 · Cited by 29 · see citing works
Unleashing the Power of Covalent Drugs for Protein Degradation
Fu, M., Jin, H., Wang, S., Shen, L., Liu, H., Liu, Y., Zheng, Y., & Dai, X. (2025) · Medicinal Research Reviews · doi:10.1002/med.22101 · Cited by 30 · see citing works
Self-citationSmall-Molecule PROTACs for Cancer Immunotherapy
Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 29 · see citing works
Gu, H., He, J., Li, Y., Mi, D., Guan, T., Guo, W., Liu, B., & Chen, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01433 · Cited by 29 · see citing works
Paired Electro‐Synthesis of Remote Amino Alcohols with/in H 2 O
Fang, X., Hu, X., Li, Q., Ni, S., & Ruan, Z. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202418277 · Cited by 28 · see citing works
Sun, C., Liu, S., Lau, J. W., Yang, H., Chen, Y., & Xing, B. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202423057 · Cited by 28 · see citing works
Ma, X., Wang, X., Chen, F., Zou, W., Ren, J., Xin, L., He, P., Liang, J., Xu, Z., Dong, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00131 · Cited by 27 · see citing works
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Li, Y., Wu, Y., Gao, S., Sun, T., & Jiang, C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.076 · Cited by 27 · see citing works
PROTAC Technology as a New Tool for Modern Pharmacotherapy
Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., Jamil, A., & Nowaczyk, A. (2025) · Molecules · doi:10.3390/molecules30102123 · Cited by 28 · see citing works
Lin, J., Chen, Z., Zhang, D., Zhang, N., Chen, H., & Guo, D. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202401051 · Cited by 26 · see citing works
Guo, W., Wang, M., Yang, Z., Liu, D., Ma, B., Zhao, Y., Chen, Y., & Hu, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115792 · Cited by 26 · see citing works
Li, Y., Li, G., Zuo, C., Wang, X., Han, F., Jia, Y., Shang, H., & Tian, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116367 · Cited by 25 · see citing works
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Thapa, R., Bhat, A. A., Gupta, G., Jyothi, S. R., Kaur, I., Kumar, S., Sharma, N., Prasad, G. V. S., Pramanik, A., & Ali, H. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70009 · Cited by 24 · see citing works
Voltage-Gated Ion Channels in Neuropathic Pain Signaling
Felix, R., Corzo-López, A., & Sandoval, A. (2025) · Life · doi:10.3390/life15060888 · Cited by 24 · see citing works
Acharyya, R. K., Rej, R. K., Hu, B., Chen, Z., Wu, D., Lü, J., Metwally, H., McEachern, D., Wang, Y., Jiang, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01521 · Cited by 23 · see citing works
Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation
Li, Y., Bao, K., Sun, J., Ge, R., Zhang, Q., Zhang, B., Yan, X., Li, J., Shi, F., Zhang, M., et al. (2025) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01537-1 · Cited by 24 · see citing works
Pan, M., Yang, C., Fu, Z., Yang, Y., Zhuo, Y., Hou, H., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202501384 · Cited by 23 · see citing works
An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti‐Solid Tumor Immunity
Yao, Y., Wu, M., Wang, Y., Liao, Z., Yang, Y., Liu, Y., Shi, J., Wu, W., Wei, X., Xu, J., et al. (2024) · Advanced Materials · doi:10.1002/adma.202411454 · Cited by 22 · see citing works
Self-citationHou, Z., Deng, L., Fang, F., Zhao, T., Zhang, Y., Li, G., Miao, M. Z., Zhang, Y., Yu, H., & Liu, X. (2025) · BMC Biology · doi:10.1186/s12915-025-02125-x · Cited by 22 · see citing works
Deng, A., Fan, R., Gou, J., Sang, R., Lin, R., Zhao, T., Zhuang, J., Hai, Y., Sun, J., & Wei, G. (2025) · Exploration · doi:10.1002/exp.20240031 · Cited by 22 · see citing works
Cai, H. X., Zhang, T., & Yuanjia, H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118055 · Cited by 22 · see citing works
He, S., Huang, W., Zhu, Y., Gao, F., Fang, Y., Zhu, J., Bao, Y., Dong, G., & Sheng, C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202511467 · Cited by 22 · see citing works
Yang, Z., Ying, Y., Cheng, S., Wu, J., Zhang, Z., Hu, P., Xiong, J., Li, H., Zeng, Q. G., Cai, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00356 · Cited by 21 · see citing works
Exploiting E3 ligases for lung cancer therapy: The promise of DCAF-PROTACs
Hussain, M. S., Eltaib, L., Rana, A. J., Maqbool, M., Ashique, S., Alanazi, M. N., Khan, Y., & Agrawal, M. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156001 · Cited by 22 · see citing works
Recent advances in targeting LRRK2 for Parkinson’s disease treatment
Karami, M., Sanaye, P. M., Ghorbani, A., Amirian, R., Goleij, P., Babamohamadi, M., & Izadi, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06354-0 · Cited by 21 · see citing works
Lu, Y., Yan, Z., Sun, J., Wang, C., Xu, L., Lyu, X., Wang, X., Lou, J., Huang, H., Meng, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02884 · Cited by 20 · see citing works
Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms
Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026) · Biomolecules · doi:10.3390/biom16020325 · Cited by 22 · see citing works
Gao, W., Gu, K., Ma, L., Yang, F., Deng, L., Zhang, Y., Miao, M. Z., Li, W., Li, G., Qian, H., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.90725 · Cited by 19 · see citing works
The application of targeted protein degradation technologies to G protein‐coupled receptors
Keen, A. C., Jörg, M., & Halls, M. L. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16079 · Cited by 19 · see citing works
Zhou, Y., Xu, S., López‐Carrobles, N., Ding, D., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0019 · Cited by 19 · see citing works
Kang, D. H., Lee, J., Im, S., & Chung, C. (2024) · Cancers · doi:10.3390/cancers16233996 · Cited by 19 · see citing works
EGFR inhibitors across generations: Progress, challenges, and future directions
Deshmukh, V. G., Sapkal, S. B., Gadekar, S. S., & Deshmukh, V. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142326 · Cited by 19 · see citing works
Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor
Kato, J., Korenaga, S., & Iwakura, M. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129083 · Cited by 18 · see citing works
- Authors
- He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y.
- Affiliations
- Tsinghua University (CN)
- Zhengzhou University (CN)
- Corresponding author
- Rao, Yu
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2022-06-09
- Volume
- 7
- Issue
- 1
- Pages
- 181-181
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC9178337
- OpenAlex
- W4281795388
- Cited by
- 283
- References
- 559
- Citations by year
- 2026: 50 · 2025: 82 · 2024: 84 · 2023: 50 · 2022: 17
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (#82125034, #81773567, 2021YFA1302100, 2020YFE0202200)
- China Postdoctoral Science Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Keywords
- PROTACs, protein degradation, bifunctional small molecules, ubiquitination, ubiquitin-proteasome system, molecular glues, small-molecule degraders, clinical development, cancer therapy
- MeSH terms
- Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
